The IMID Forum
The Immune-Mediated Inflammatory Disease Forum
EN400 episodes
education
Keeping you up to date with the latest and most important updates in immune-mediated inflammatory diseases.
Notable Guests
Episodes (400)
Highlights Podcast: IL-17 Inhibition: Controlling inflammation and disease progr...
The IMID Forum
Apr 16, 202532:21pending
Discussing PsA: JAKi Comparative safety & Burden and determinants of multi‑b/tsD...
The IMID Forum
Apr 3, 202529:23pending
Discussing RA: Pain reduction & choosing second-line DMARDs after unresponsive f...
The IMID Forum
Mar 27, 202521:40pending
Author Interview: Professor Phillip Helliwell, March 2025
The IMID Forum
Mar 20, 202522:30pending
Author Interview: Professor Phillip Helliwell, 2025
The IMID Forum
Mar 13, 202526:36pending
Discussing PsA: Bimekizumab improves patient-reported outcomes and work producti...
The IMID Forum
Mar 6, 202532:04pending
Discussing RA: Baricitinib dose reduction and switching to bDMARDs vs JAKis
The IMID Forum
Feb 27, 202511:17pending
Discussing axSpA: Long-term safety and efficacy of Bimekizumab results from BE-A...
The IMID Forum
Feb 27, 202525:05pending
Author Interview: Professor Denis McGonagle, 2025
The IMID Forum
Feb 6, 202536:01pending
Discussing RA: Insights into sustained DMARD-free remission and barriers to CAR...
The IMID Forum
Jan 23, 202511:18pending
Discussing AxSpA Podcast: Efficacy and Safety of Upadacitinib
The IMID Forum
Dec 19, 202418:42pending
Discussing RA: Insights into Filgotinib and Tofacitinib in RA
The IMID Forum
Dec 19, 202424:13pending
Discussing PsA: DISCOVER-2 and BE OPTIMAL/BE COMPLETE post-hoc analyses
The IMID Forum
Nov 28, 202430:53pending
ACR 2024 Review Podcast
The IMID Forum
Nov 28, 202450:04pending
Discussing RA: Insights into Filgotinib and Tofacitinib in RA
The IMID Forum
Nov 14, 202419:16pending
Webinar Highlights Podcast: CAR T-cell Therapy: An Emerging Therapy in Autoimmun...
The IMID Forum
Nov 13, 202426:39pending
ACR 2024 Highlights: Day 2
The IMID Forum
Nov 11, 20243:36pending
ACR 2024: Preview Podcast
The IMID Forum
Nov 11, 202419:51pending
ACR 2024 Highlights: Day 3
The IMID Forum
Nov 11, 20244:21pending
ACR 2024 Highlights: Day 1
The IMID Forum
Nov 11, 20242:55pending
AxSpA Podcast: Efficacy and Safety of IV secukinumab
The IMID Forum
Oct 31, 202423:30pending
Discussing RA: Navigating JAKis, TNFis, and the quest for optimal RA therapy
The IMID Forum
Oct 31, 202422:03pending
Author Interview: Derin Karacabeyli, 2024
The IMID Forum
Oct 10, 202433:27pending
Webinar Highlights Podcast 2: Evolving Therapeutic Strategies for Psoriatic Dise...
The IMID Forum
Oct 7, 202432:56pending
PsA Podcast: Bimekizumab: Efficacy, safety, and effectiveness in PsA
The IMID Forum
Sep 26, 202421:04pending
Discussing RA: Long-term safety and efficacy of upadacitinib in SELECT trials
The IMID Forum
Sep 19, 202419:24pending
Discussing AxSpA: Incidence of uveitis following bimekizumab treatment
The IMID Forum
Aug 29, 202424:11pending
Author Interview: Professor Laura Andreoli, 2024
The IMID Forum
Aug 22, 202444:09pending
Discussing RA: Neutrophil-to-lymphocyte ratio and treatment response to filgotin...
The IMID Forum
Aug 15, 202416:05pending
Discussing PsA: Guselkumab and analysis of genetic markers
The IMID Forum
Aug 12, 202425:46pending
IMID Author Interview: Dr Blanca Hernández-Cruz, 2024
The IMID Forum
Aug 12, 202433:50pending
Discussing RA: March 2024
The IMID Forum
Aug 12, 20248:39pending
Discussing RA: January 2024
The IMID Forum
Aug 12, 20249:43pending
Discussing RA: February 2024
The IMID Forum
Aug 12, 202410:17pending
Discussing PsA: Secukinumab & The Effect of Sex on the Long-Term Persistence of...
The IMID Forum
Aug 12, 202430:33pending
Discussing PsA: Long-term safety of ixekizumab & bimekizumab treatment in a TNFi...
The IMID Forum
Aug 12, 202438:13pending
Discussing PsA: Clinical Response to Guselkumab & Sequential Lines of b/tsDMARDs
The IMID Forum
Aug 12, 202432:10pending
Discussing PsA: Bimekizumab therapy in PsA
The IMID Forum
Aug 12, 202429:49pending
Discussing PsA: 2023 EULAR recommendations and improvements in PROs with deucrav...
The IMID Forum
Aug 12, 202428:33pending
Discussing AxSpA: Upadacitinib in nr-axSpA and certolizumab pegol by baseline MR...
The IMID Forum
Aug 12, 202422:14pending
Discussing AxSpA: Risk of Uveitis with Different bDMARDs & PROs following Secuki...
The IMID Forum
Aug 12, 202432:38pending
Discussing AxSpA: Long-term etanercept response & real-world effectiveness of to...
The IMID Forum
Aug 12, 202429:48pending
Discussing AxSpA: Long-Term Outcomes of Secukinumab & JAKis in Clinical Practice
The IMID Forum
Aug 12, 202425:05pending
Discussing AxSpA: Secukinumab retention over time & sacroiliac joint improvement...
The IMID Forum
Aug 12, 202433:01pending
Discussing AxSpA: Bimekizumab in AxSpA & Secukinumab Patient Clustering
The IMID Forum
Aug 12, 202426:26pending
Author Interview: Dr Adam Goldman, 2024
The IMID Forum
Aug 8, 202421:07pending
Author Interview: Professor Daniel Blockmans, 2024
The IMID Forum
Jul 25, 202426:44pending
Discussing RA: July 2024
The IMID Forum
Jul 18, 202423:23pending
Discussing RA: June 2024
The IMID Forum
Jun 27, 202425:59pending
EULAR 2024 Review Podcast
The IMID Forum
Jun 19, 202436:38pending
...